Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OVU Plus is a fixed-dose combination nutraceutical product developed by Medcell Pharma for the management of polycystic ovary syndrome (PCOS) and associated female infertility. It is formulated as chewable tablets containing myo-inositol, D-chiro-inositol, vitamin D3 (cholecalciferol), L-methylfolate (levomefolic acid), and berberine. The combination of myo-inositol and D-chiro-inositol in a specific ratio is designed to improve insulin sensitivity, restore ovulatory function, and reduce hyperandrogenism. Berberine further supports metabolic health and insulin sensitivity, while vitamin D3 and L-methylfolate address nutritional deficiencies and support overall reproductive health and oocyte quality.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on OVU Plus.